Oncolytics Net Debt vs Retained Earnings Analysis
ONCY Stock | USD 1.13 0.03 2.59% |
Oncolytics Biotech financial indicator trend analysis is much more than just breaking down Oncolytics Biotech prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Oncolytics Biotech is a good investment. Please check the relationship between Oncolytics Biotech Net Debt and its Retained Earnings accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.
Net Debt vs Retained Earnings
Net Debt vs Retained Earnings Correlation Analysis
The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Oncolytics Biotech Net Debt account and Retained Earnings. At this time, the significance of the direction appears to have fragmental relationship.
The correlation between Oncolytics Biotech's Net Debt and Retained Earnings is 0.43. Overlapping area represents the amount of variation of Net Debt that can explain the historical movement of Retained Earnings in the same time period over historical financial statements of Oncolytics Biotech, assuming nothing else is changed. The correlation between historical values of Oncolytics Biotech's Net Debt and Retained Earnings is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Net Debt of Oncolytics Biotech are associated (or correlated) with its Retained Earnings. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Retained Earnings has no effect on the direction of Net Debt i.e., Oncolytics Biotech's Net Debt and Retained Earnings go up and down completely randomly.
Correlation Coefficient | 0.43 |
Relationship Direction | Positive |
Relationship Strength | Weak |
Net Debt
The total debt of a company minus its cash and cash equivalents. It represents the actual debt burden on the company after accounting for the liquid assets it holds.Retained Earnings
The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.Most indicators from Oncolytics Biotech's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Oncolytics Biotech current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.At this time, Oncolytics Biotech's Selling General Administrative is fairly stable compared to the past year. Enterprise Value is likely to rise to about 118.3 M in 2024, whereas Tax Provision is likely to drop slightly above 84.1 K in 2024.
2021 | 2022 | 2023 | 2024 (projected) | Interest Income | 98.6K | 528K | 1.2M | 1.2M | Net Interest Income | 98.6K | 528K | 1.2M | 1.2M |
Oncolytics Biotech fundamental ratios Correlations
Click cells to compare fundamentals
Oncolytics Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Oncolytics Biotech fundamental ratios Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Total Current Liabilities | 12.9M | 2.7M | 2.7M | 3.9M | 4.2M | 3.9M | |
Total Stockholder Equity | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 17.8M | |
Property Plant And Equipment Net | 727.5K | 609.1K | 976.3K | 652K | 647K | 460.6K | |
Net Debt | (13.6M) | (30.8M) | (40.6M) | (11.3M) | (31.1M) | (29.6M) | |
Retained Earnings | (344.6M) | (367.1M) | (393.4M) | (418.3M) | (446.0M) | (423.7M) | |
Accounts Payable | 3.2K | 1.8K | 594K | 2.3M | 1.1M | 1.0M | |
Cash | 14.1M | 31.2M | 41.3M | 11.7M | 31.5M | 19.3M | |
Non Current Assets Total | 727.5K | 609.1K | 976.3K | 1.7M | 647.0K | 614.6K | |
Cash And Short Term Investments | 14.1M | 31.2M | 41.3M | 32.1M | 34.9M | 26.6M | |
Net Receivables | 2.1M | 89.7K | 866.1K | 521K | 15K | 14.3K | |
Common Stock Shares Outstanding | 22.1M | 40.3M | 53.5M | 58.0M | 67.6M | 71.0M | |
Liabilities And Stockholders Equity | 19.7M | 34.3M | 45.9M | 37.3M | 38.8M | 30.5M | |
Non Current Liabilities Total | 6.9M | 6.9M | 7.1M | 6.9M | 7.0M | 7.4M | |
Other Current Assets | 2.7M | 2.4M | 2.8M | 3.0M | 3.2M | 3.4M | |
Other Stockholder Equity | 33.0M | 34.6M | 37.8M | 40.1M | 42.1M | 38.2M | |
Total Liab | 19.8M | 9.6M | 9.8M | 10.8M | 11.3M | 6.0M | |
Property Plant And Equipment Gross | 1.7M | 609.1K | 976.3K | 652K | 1.3M | 1.4M | |
Total Current Assets | 18.9M | 33.7M | 44.9M | 35.7M | 38.2M | 28.0M | |
Accumulated Other Comprehensive Income | 464.1K | 400.2K | 387.7K | 662K | 544K | 516.8K | |
Other Current Liab | 12.5M | 2.5M | 2.4M | 1.5M | 4.1M | 4.3M | |
Other Liab | 4.6M | 5.9M | 6.7M | 6.7M | 7.7M | 8.1M | |
Net Tangible Assets | (107.9K) | 24.8M | 36.1M | 26.5M | 30.5M | 32.0M | |
Common Stock Total Equity | 271.7M | 285.2M | 311.1M | 356.8M | 410.3M | 430.9M | |
Short Term Investments | 13.1M | 30.4M | 1.4M | 20.5M | 3.4M | 3.2M | |
Short Term Debt | 339.8K | 248.9K | 293.7K | 216K | 133K | 127.3K | |
Common Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 452.5M | |
Property Plant Equipment | 727.5K | 609.1K | 976.3K | 652K | 749.8K | 377.8K | |
Capital Lease Obligations | 506.3K | 402.1K | 654.8K | 373K | 423K | 288.3K | |
Current Deferred Revenue | (3.2K) | (1.8K) | (594K) | (1.1M) | (973.8K) | (925.1K) | |
Net Invested Capital | (107.9K) | 24.8M | 36.1M | 26.5M | 27.6M | 20.3M | |
Net Working Capital | 6.1M | 31.0M | 42.2M | 31.7M | 33.9M | 26.6M | |
Capital Stock | 311.1M | 356.8M | 391.3M | 404.0M | 430.9M | 399.6M |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.C | Citigroup | |
CRM | Salesforce | |
MSFT | Microsoft |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Oncolytics Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Oncolytics Stock please use our How to Invest in Oncolytics Biotech guide.Note that the Oncolytics Biotech information on this page should be used as a complementary analysis to other Oncolytics Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Center module to all portfolio management and optimization tools to improve performance of your portfolios.
Complementary Tools for Oncolytics Stock analysis
When running Oncolytics Biotech's price analysis, check to measure Oncolytics Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Oncolytics Biotech is operating at the current time. Most of Oncolytics Biotech's value examination focuses on studying past and present price action to predict the probability of Oncolytics Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Oncolytics Biotech's price. Additionally, you may evaluate how the addition of Oncolytics Biotech to your portfolios can decrease your overall portfolio volatility.
Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
Global Correlations Find global opportunities by holding instruments from different markets | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Share Portfolio Track or share privately all of your investments from the convenience of any device | |
Commodity Directory Find actively traded commodities issued by global exchanges | |
Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is Oncolytics Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Oncolytics Biotech. If investors know Oncolytics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Oncolytics Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.29) | Return On Assets (0.64) | Return On Equity (1.16) |
The market value of Oncolytics Biotech is measured differently than its book value, which is the value of Oncolytics that is recorded on the company's balance sheet. Investors also form their own opinion of Oncolytics Biotech's value that differs from its market value or its book value, called intrinsic value, which is Oncolytics Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Oncolytics Biotech's market value can be influenced by many factors that don't directly affect Oncolytics Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Oncolytics Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if Oncolytics Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Oncolytics Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.